Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation

Roberto Crocchiolo, Carla Canevari, Andrea Assanelli, Francesca Lunghi, Michela Tassara, Maria Lupo Stanghellini, Daniela Clerici, Claudio Landoni, Paolo Servida, Massimo Bernardi, Jacopo Peccatori, Andres Ferreri, Luigi Gianolli, Claudio Bordignon, Federico Caligaris-Cappio, Fabio Ciceri, Ferruccio Fazio

Research output: Contribution to journalArticle

Abstract

We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 with Hodgkin Lymphoma (HL) and 39 with non-Hodgkin Lymphoma (NHL), treated between February 1999 and October 2006 at our institution, who had a pre-ASCT FDG-PET (pPET) evaluation. Median age was 45 years (range: 18-69). After a median follow-up of 31 months (range: 8-91), 7 out of 16 pPET+ patients and 10 out of 37 pPET- patients experienced lymphoma relapse. The 5-year OS is 90% and 55% (p = 0.01) in patients with negative and positive pPET, respectively. In conclusion, a positive pPET indicates a poorer outcome after ASCT with respect to a negative pPET; this subset of patients should be considered candidate to more intensive or investigational approaches.

Original languageEnglish
Pages (from-to)727-733
Number of pages7
JournalLeukemia and Lymphoma
Volume49
Issue number4
DOIs
Publication statusPublished - Apr 2008

Keywords

  • FDG-PET
  • Autologous stem cell transplantation
  • High-dose sequential chemotherapy
  • Lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this